Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: This will be a randomized double blind study which will be conducted on patients admitted to Department of Hepatology from June 2013 to may 2014 at ILBS, New Delhi. Patients not having any exclusion criteria will undergo bone marrow examination and liver biopsy at the baseline.

60 patients of decompensated cirrhosis will be randomised into two limbs- limb A (30 patients) will receive G-CSF and erythropoietin while those on limb B (30 patients) will receive G-CSF alone. The drugs will be given for 2 months and patient will be followed for 1 year. G-CSF will be given at a dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 60 (total 22 doses). Erythropoietin will be given s/c at dose of 500 IU/Kg twice a week for 2 months.

Follow up will be done on days 0,3,7,14,28, day 42 (6 weeks), day 60 (2 months), day 90 (3 months), day 180 (6 months), day 270 (9 months); and day 360 (1 year).


Options:
A: Arm Label: G-CSF + steroid in partial responder; Type: EXPERIMENTAL; Interventions: Drug: G-CSF (Filgrastim injection), Drug: steroid | Arm Label: Placebo + steroid in partial responder; Type: PLACEBO_COMPARATOR; Interventions: Drug: steroid, Drug: placebo | Arm Label: G-CSF in null responder to steroid; Type: EXPERIMENTAL; Interventions: Drug: G-CSF (Filgrastim injection) | Arm Label: Placebo in null responder to steroid; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: G-CSF (Filgrastim injection); Assigned to Arm(s): G-CSF + steroid in partial responder, G-CSF in null responder to steroid | Intervention Type: DRUG; Name: steroid; Assigned to Arm(s): G-CSF + steroid in partial responder, Placebo + steroid in partial responder | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo + steroid in partial responder, Placebo in null responder to steroid
B: Arm Label: Standard Medical therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: standard medical therapy | Arm Label: G-CSF; Type: EXPERIMENTAL; Interventions: Drug: standard medical therapy, Drug: G-CSF | Arm Label: G-CSF and NAC; Type: EXPERIMENTAL; Interventions: Drug: standard medical therapy, Drug: G-CSF, Drug: n-Acetylcysteine | Intervention Type: DRUG; Name: standard medical therapy; Assigned to Arm(s): G-CSF, G-CSF and NAC, Standard Medical therapy | Intervention Type: DRUG; Name: G-CSF; Assigned to Arm(s): G-CSF, G-CSF and NAC | Intervention Type: DRUG; Name: n-Acetylcysteine; Assigned to Arm(s): G-CSF and NAC
C: Arm Label: G-CSF + Erythropoietin; Type: EXPERIMENTAL; Interventions: Drug: G-CSF | Arm Label: G-CSF; Type: ACTIVE_COMPARATOR; Interventions: Drug: G-CSF+Erythropoetin | Intervention Type: DRUG; Name: G-CSF+Erythropoetin; Assigned to Arm(s): G-CSF | Intervention Type: DRUG; Name: G-CSF; Assigned to Arm(s): G-CSF + Erythropoietin
D: Arm Label: Granulocyte colony-stimulating factor; Type: EXPERIMENTAL; Interventions: Drug: Granulocyte colony-stimulating factor, Drug: standard treatment | Arm Label: standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: standard treatment | Intervention Type: DRUG; Name: Granulocyte colony-stimulating factor; Assigned to Arm(s): Granulocyte colony-stimulating factor | Intervention Type: DRUG; Name: standard treatment; Assigned to Arm(s): Granulocyte colony-stimulating factor, standard treatment

Answer: C